VANCOUVER, BRITISH COLUMBIA–(Sept. 23, 2014) – Supreme Pharmaceuticals Inc. (the “Company”) (OTCBB:SPRWF) (CSE:SL) is pleased to announce the appointment of Chris Bechtel to its advisory board. Mr. Bechtel brings a wealth of experience in capital markets, start-ups, and medicinal marijuana to the Company.

Mr. Bechtel launched a small business in the oil and gas industry in Houston, Texas in 1983 at the age of 23, which he then grew to revenues of over $30 million in six countries. In 2006, Mr. Bechtel sold his business to Weatherford International, one of the largest global providers of oil and gas services. Mr. Bechtel continues to run the original labs business, as well as other divisions for Weatherford, representing a combined staff of 2,500 employees and gross revenues of approximately $500M.

Mr. Bechtel became deeply involved in the marijuana industry after investigating the medical benefits of cannabis for an immediate family member. This led Mr. Bechtel to become a private investor in, and consultant and advisor to, over half-a-dozen companies in the cannabis sector.

“We are thrilled by this addition to our team,” said David Stadnyk, President and CEO of Supreme Pharmaceuticals. “Chris has a deep understanding of the cannabis industry, knows how to grow and run a large multinational business, and brings great strategic value to the Company.”

Mr. Bechtel stated, “Growing a fledgling startup into a successful international business was one of the most gratifying experiences of my career; Supreme is well on its way to taking the same journey, and I am excited to be able to support that process in an industry that can bring so many benefits to so many people.”

VANCOUVER, BRITISH COLUMBIA–(Sept. 22, 2014) –

NOT FOR DISSEMINATION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW.

Supreme Pharmaceuticals Inc. (“Supreme” or the “Company“) (CSE:SL) is pleased to announce that it has closed the first tranche of its previously announced unit financing (see news releases dated August 15^th and September 4, 2014) for total gross proceeds of $2,239,232.50 (the “Financing“). At closing, Supreme issued 8,956,930 Units (comprised of 8,956,930 common shares of the Company (“Common Shares“) and 4,478,465 Common Share purchase warrants (“Warrants“)) at a price of $0.25 per Unit. Each Warrant is exercisable for one Common Share at a price of $0.50 per share prior to September 22, 2015, subject to an accelerated expiry period upon 30-days notice by the Corporation to the subscriber, if the Common Shares trade at or above $0.70 for any five (5) day period during the term of the Warrants. Directors, senior officers and other insiders of the Corporation purchased an aggregate of 660,000 Units pursuant to the Financing. The Company paid finder’s fees of $65,320 and issued 287,280 Warrants to certain arm’s-length parties in the connection with the subscriptions of certain subscribers who participated in the private placement.

The Common Shares and Warrants issued pursuant to the private placement are subject to a hold period that expires January 23, 2015. Following closing, Supreme has 68,341,565 Common Shares issued and outstanding.

The Company intends to use the proceeds of the Financing for the development of the Company’s Kincardine facility and general working capital purposes. Based on the number of investors who have already submitted subscription agreements for the final tranche of the Financing, Supreme anticipates moving quickly towards a second closing prior to the end of September.

FORWARD-LOOKING INFORMATION

This news release contains forward‐looking statements and forward‐looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward‐looking statements or information. More particularly and without limitation, this news release contains forward‐looking statements and information relating to the use of proceeds of the private placement, as well as the Company’s corporate strategy, participation in second tranche by those investors who have submitted subscription agreements to the Company but were not included in the first tranche, and having sufficient subscribers to close a second tranche. The forward‐looking statements and information are based on certain key expectations and assumptions made by management of the Corporation, including, without limitation, the Company’s ability to complete the remainder of the private placement. Although management of the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward‐looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Corporation relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward‐looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company’s ability to identify and complete additional suitable acquisitions to further the Company’s growth as well as risks associated with the medical marijuana industry in general such as operational risks in development and production delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and related regulations. Accordingly, readers should not place undue reliance on the forward‐looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.

The forward‐looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward‐looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

VANCOUVER, BRITISH COLUMBIA–(Sept. 4, 2014) – Supreme Pharmaceuticals Inc. (the “Company”) (CSE:SL) wishes to announce its intention to offer securities under of the previously announced non-brokered private placement (see news release dated August 15^th, 2014) of up to 20 million units in the capital of the corporation (“Units”) at a price of $0.25 per Unit for aggregate gross proceeds of up to $5,000,000 (the “Financing”) to existing holders of common shares of the Corporation (“Existing Shareholders”). Any Existing Shareholder of Supreme as at September 3, 2014 will be eligible to purchase Units pursuant to the recently adopted “existing security holder” prospectus exemption in all Canadian jurisdictions other than Ontario and Newfoundland. Under the new regulation, there is no longer a need for an existing shareholder to qualify under the “accredited investor” exemption in order to participate in the Financing, however subscribers who do not receive advice regarding the suitability of their investment from a registered investment dealer may not purchase more than $15,000 of securities of Supreme under this exemption in any 12 month period.

In the event there is an over subscription of shares, the Company reserves the right to either reject subscriptions at its discretion, allocate on a pro rata basis or increase the size of the Financing. It is anticipated that the offering will be open until September 19^th, 2014.

A director of the Company stated, “The amendment to the financing is an avenue that allows us to include our valued shareholders that wish to participate in our current placement. In addition, the new brand and fully integrated website bring the Company one step closer to its goal of becoming a commercial producer of medical marijuana.”

In addition, the company pleased to report that it has recently undergone a major rebranding and developed a new website infrastructure complete with online store, corporate information, news, doctor’s hub, and more. The new brand and website are anticipated to launch on Monday, September 8^th, 2014 at www.supreme.ca.

FORWARD-LOOKING INFORMATION

This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the closing date of the Offering, the availability of the “existing security holder” exemption for purchases of Units under the Financing and the launch date for the new website. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com and such factors as the Company failing to close the offering, the Units not being eligible for purchase through certain exemptions from the prospectus requirement and failure to launch the website as anticipated. This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995..

VANCOUVER, BRITISH COLUMBIA–(Aug. 28, 2014) – Supreme Pharmaceuticals Inc. (“Supreme” or the “Company”) (OTCBB:SPRWF)(CSE:SL) is pleased to announce Brayden R. Sutton as Executive Vice President.

Mr. Sutton will be responsible to oversee operations, assisting in the overall design and completion of the facilities, marketing, financing and business development.

Mr. Sutton has been involved on the research and analysis side of cannabis and cannabis related businesses for over 10 years. Brayden has a thorough understanding of the science of cannabis, the patients who use it, and close ties to the physician community.

He brings over 12 years of successful experience in the capital markets as an investor and financier since 2002 as well as extensive management and operational experience overseeing large-scale projects. He is also President and CEO of CannabisHealth.com as well as having served as the only Canadian Analyst for 420Investor.com.

David Stadnyk, President and CEO stated:

“We are very pleased Brayden is joining the Company as he will be a great addition to our management team with his thorough knowledge of the industry and deep understanding of our business”.

FORWARD LOOKING INFORMATION

This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the up grading of the facility, the timing on completion of the MMPR License conditions and the start of production. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com and such factors as the Company failing to finish the upgrading of the facility and put the same into production in accordance within the terms of the MMPR license. This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995.